Study: Poverty Linked to Higher Risk of Death Among Children with Cancer Undergoing Stem Cell Transplantation – PRNewswire

WASHINGTON, Oct. 26, 2020 /PRNewswire/ --Despite the increasing use and promise of hematopoietic cell transplantation (HCT) as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children transplanted for cancer are more likely to die from treatment-related complications if they live in poorer neighborhoods. The study, published today in the journal Blood, also found that having Medicaid versus private insurance, another marker of poverty, was associated with a higher chance of dying. Researchers say the results underscore the need to better understand and mitigate the effects of poverty and other social determinants of health on pediatric cancer care.

Hematopoietic cell transplantation, also called stem cell or bone marrow transplantation, is a treatment option for patients with blood cancers such as leukemia or lymphoma, as well as certain non-malignant conditions such as sickle cell disease or immunodeficiencies. It is only accessible at some medical centers. Together with radiation therapy or chemotherapy, HCT is designed to increase the chance of eliminating the cancerous or abnormal blood cells, and of restoring normal blood cell production.

The data revealed that children under the age of 18 with cancer who live in communities with high poverty rates had a 34% greater risk of treatment-related mortality following HCT compared with children in low-poverty areas. Even after adjusting for a child's disease and transplant-related factors, the data revealed children on Medicaid had a 23% greater risk of dying from any cause within five years of undergoing HCT and a 28% greater risk of treatment-related mortality when compared to children with private insurance.

"Our study shows that even after children with cancer have successfully accessed this high-resource treatment at specialized medical centers, those who are exposed to poverty are still at higher risk of dying of complications after treatment and of dying overall," said lead author Kira Bona, MD, MPH, Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. "Simply providing the highest quality complex medical care to children who are vulnerable from a social perspective is inadequate if our goal is to cure every child with cancer."

One in five children in the U.S. lives in a household with an income below the federal poverty level. While previous studies have shown an association between household poverty and poorer outcomes in HCT procedures generally, there are limited data on how poverty influences the success of HCT in children specifically.

Dr. Bona and her team sought to fill this gap by reviewing outcomes data for pediatric allogeneic transplant recipients from the Center for International Blood and Marrow Transplant Research Database, the largest available repository of HCT outcomes. The researchers looked at two cohorts of patients: 2,053 children with malignant disease and 1,696 children with non-malignant disease, who underwent a first HCT between 2006 and 2015. Neighborhood poverty exposure was defined according to U.S. Census definitions as living within a ZIP code in which 20% or more of the residents live below 100% of the Federal Poverty Level. They also stratified patients by type of insurance and used Medicaid as a proxy measure for household level poverty. The researchers looked at pediatric patients' overall survival defined as the time from HCT until death from any cause, as well as relapse, transplant-related mortality, acute and chronic graft-versus-host disease, and infection in the first 100 days following HCT.

Interestingly, neighborhood poverty or having Medicaid insurance did not seem to affect outcomes, including overall survival, relapse, or infection, among children transplanted for non-malignant diseases such as sickle cell disease. Dr. Bona said the study does not explain why this might be and more research is needed; however, it is possible that physicians and families of children with non-malignant conditions who face social health challenges may elect to avoid intensive HCT procedures.

One study limitation is its reliance on proxy measures of household poverty (ZIP code and Medicaid insurance) that do not provide insight into specific aspects of an individual child's socioeconomic exposures and the home environment in which they live that may interfere with their ability to navigate the health care system. Dr. Bona says researchers and clinicians have historically not considered social determinants of health as being as important as biological variables in specialized cancer care and so have not collected data on these factors as part of research. She says this is a missed opportunity.

"We as a field need to recognize that non-biological variables such as your exposure to poverty and other social determinants of health matter just as much as many of the biological variables we pay close attention to when thinking about outcomes for children, and these variables must be collected systematically for research if we want to optimize the care and outcomes of the children we serve," Dr. Bona said.

If future studies could collect more nuanced measures of poverty such as household material hardship (e.g., food insecurity, access to heat and electricity, housing insecurity, transportation insecurity) or language barriers, targeted interventions in the form of assistance programs could potentially help mitigate social hardships and improve the overall care of children with cancer.

Blood(www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).

SOURCE American Society of Hematology/Blood Journal

http://www.bloodjournal.org

The rest is here:
Study: Poverty Linked to Higher Risk of Death Among Children with Cancer Undergoing Stem Cell Transplantation - PRNewswire

NK Cell Therapy and Stem Cell Therapy Industry Market Size, Global Analytical Overview, Key Players, Regional Demand, Trends and Forecast To 2026 -…

A recent market research report added to repository of Credible Markets is an in-depth analysis of Global NK Cell Therapy and Stem Cell Therapy Industry Market. On the basis of historic growth analysis and current scenario of NK Cell Therapy and Stem Cell Therapy Industry market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools that facilitate deeper understanding of multiple aspects of global NK Cell Therapy and Stem Cell Therapy Industry market. This further helps users with their developmental strategy.

This report examines all the key factors influencing growth of global NK Cell Therapy and Stem Cell Therapy Industry market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global NK Cell Therapy and Stem Cell Therapy Industry market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

For Better Understanding, Download FREE Sample Copy of NK Cell Therapy and Stem Cell Therapy Industry Market Report @ https://www.crediblemarkets.com/sample-request/nk-cell-therapy-and-stem-cell-therapy-industry-market-38803

Data presented in global NK Cell Therapy and Stem Cell Therapy Industry market report allows users to realize their market entry potential and devise fruitful developmental strategies to fulfil their business goals. A report sample can be requested to view the report outline before you actually purchase it.

Key players in the global NK Cell Therapy and Stem Cell Therapy market covered in Chapter 12:

Osiris Therapeutics Chiesi Pharmaceuticals Molmed Takeda Pharmaceutical Medi-post Chipscreen Biosciences Affimed NV JCR Pharmaceutical Pharmicell Innate Pharma SA NuVasive Anterogen Altor BioScience Corporation

In Chapter 4 and 14.1, on the basis of types, the NK Cell Therapy and Stem Cell Therapy market from 2015 to 2025 is primarily split into:

NK Cell Therapy Stem Cell Therapy

In Chapter 5 and 14.2, on the basis of applications, the NK Cell Therapy and Stem Cell Therapy market from 2015 to 2025 covers:

Hospital & clinics Regenerative medicine centers Diagnostic centers Research institutes Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.crediblemarkets.com/enquire-request/nk-cell-therapy-and-stem-cell-therapy-industry-market-38803

Some Points from Table of Content

COVID-19 Outbreak-Global NK Cell Therapy and Stem Cell Therapy Industry Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Chapter 1 NK Cell Therapy and Stem Cell Therapy Industry Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global NK Cell Therapy and Stem Cell Therapy Industry Market, by Type

Chapter 5 NK Cell Therapy and Stem Cell Therapy Industry Market, by Application

Chapter 6 Global NK Cell Therapy and Stem Cell Therapy Industry Market Analysis by Regions

Chapter 7 North America NK Cell Therapy and Stem Cell Therapy Industry Market Analysis by Countries

Chapter 8 Europe NK Cell Therapy and Stem Cell Therapy Industry Market Analysis by Countries

Chapter 9 Asia Pacific NK Cell Therapy and Stem Cell Therapy Industry Market Analysis by Countries

Chapter 10 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Industry Market Analysis by Countries

Chapter 11 South America NK Cell Therapy and Stem Cell Therapy Industry Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global NK Cell Therapy and Stem Cell Therapy Industry Market Forecast

Chapter 15 New Project Feasibility Analyses

Direct Purchase NK Cell Therapy and Stem Cell Therapy Industry Market Research Report Now @ https://www.crediblemarkets.com/reports/purchase/nk-cell-therapy-and-stem-cell-therapy-industry-market-38803?license_type=single_user

Points Covered in the Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Impact of Covid-19 in NK Cell Therapy and Stem Cell Therapy Industry Market: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the NK Cell Therapy and Stem Cell Therapy Industry market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Browse the Short Summary & TOC of the Report @ https://www.crediblemarkets.com/reports/nk-cell-therapy-and-stem-cell-therapy-industry-market-38803

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Read more:
NK Cell Therapy and Stem Cell Therapy Industry Market Size, Global Analytical Overview, Key Players, Regional Demand, Trends and Forecast To 2026 -...

Ask Amy: First cancer hits, then heartbreak follows – The Providence Journal

Dear Amy,

Three years ago, I was diagnosed with bone cancer.

I went through 2 years of chemotherapy and six months of stem cell treatment.

I am now deemed to be cancer-free, and I feel great compared to how I felt in those three years.

During that time, I was with a woman (for eight years). We did everything together: Movies, dinners, road trips. Never had an argument. Never raised our voices at each other. My family and friends all loved her, as did I.

She treated me lovingly when I was sick, but of course when I was ill, I couldn't do the things we used to do. I hated that. My sex drive was gone. But I got better. I started feeling like my old self.

Then I was hit with a bombshell. She left me two months after I got well.

I was crushed. Heartbroken. I cried like a baby. I asked her why, and she said she felt like she was only existing. Not living.

But I was getting better!

I think that she met someone while I was ill, and she chose the other person. It hurts so deeply. My family, friends and her daughter were devastated.

She said, "We both need to move on with our lives," and I'm trying, but it's hard.

What do I do now? Besides go on with my life?

I'm working again, but it is tough by myself. I know I won't give up or give in, but this still hurts.

Do you have any words of wisdom for me?

Heartbroken in Dallas

Conventional wisdom might suggest that someone who hangs in there through the worst of things would then breathe a sigh of relief and commit to being there during recovery. But people leave. Your partner might have been exhausted by the caregiving she did during the worst of your illness.

I suspect that she might have wanted to leave just before, or maybe during your illness, but hung in there out of duty, guilt, loyalty, or compassion for you.

And what you must do now is go on with your life.

You are already doing this, in gradual steps that will become strides. Your recovery from this extremely painful breakup might parallel your recovery from cancer. Look at each day and celebrate your smaller victories. Write them down: A good day at work, a conversation with a friend, a creative project started or completed, an extra lap around the track, increased physical strength, another day of cancer-free living. You are demonstrating impressive resilience and strength. Recognizing that - deep down - will be an important building block for the new and improved you.

Dear Amy,

Every time my mom put dinner on the table I said, "Thank you," up until her death, and I am 56.

It is not just a family thing. When I prepare meals for friends, family, work colleagues or when we go out, it seems that saying thank you after a meal is the norm.

I now live with my fiance. His son just spent a month visiting us.

Every night I prepared and provided a healthy, home-cooked meal: Garden vegetables, shrimp, filet, pork, fish, different salads and grains.

Never once did I get a "thank you."

The last night, I even said, "I hope a different meal routine and food variety was a nice change." He actually said, "Nah, I always manage."

The lack of expression of gratitude infuriates me.

To be fair, most other aspects of the visit went well.

What are my best options to communicate this? It would be hard to cover up my resentment.

Gracious, Resentful Cook

Don't blame your fiance's son for not biting the hook during your attempt to fish for gratitude and a compliment. He sounds unsophisticated.

But there is another person at the table: his father. Your fiance should model kindness, respect and gratitude acknowledging your effort before eating and thanking you afterward and show his son that a grateful diner also clears the table and cleans up after a delicious meal.

Dear Amy,

I'm curious why the "Anxious Wife" whose husband didn't do enough housework neglected to state the working (outside the home) status of her and/or her husband.

Surely, if one of them is the major breadwinner, then the stay-at-home partner would be expected to perform more of the chores?

Need Clarification

"Anxious Wife" said she "needed help" with some tasks, and (regardless of their work status) I took her word for it.

Write to Ask Amy, P.O. Box 194, Freeville, NY 13068, or email askamy@amydickinson.com.

More:
Ask Amy: First cancer hits, then heartbreak follows - The Providence Journal

Stem Cell Therapy Market 2020 In-depth Analysis by Leading Players The Think Curiouser – The Think Curiouser

The report on the Stem Cell Therapy Market has been correctly designed to present multidimensional information on current and past market occurrences that tend to directly affect the future growth trajectory of this market. This section of the Stem Cell Therapy Market report provides real insights and actionable clues on progress by region, as well as country-based advances, including product and service portfolio development. The reports main focus includes details on Europe, North America, APAC, MEA and South America. This section of the report provides the report readers with important details of the soaring developments in the competitive spectrum and highlights key advances in M&A investments, notable commercial contracts, etc. by key market players taking advantage of the growth prognosis.

Download Sample PDF Brochure with Covid-19 Updates @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

The report includes details related to various vendor activities, trend analysis, DROT assessments and potential business decisions to ensure a successful position despite the ongoing intensity of competition. This high-end strategy-based Stem Cell Therapy Market report presentation presents market size and dynamics, dominant and popular trends, market shares, investment plans, pricing strategies and drivers leading to overall steady and long-term growth in the Stem Cell Therapy Market as a whole. The Stem Cell Therapy Market, based on unbiased and uncompromising research mediated by research experts, is heading towards tremendous growth and unparalleled industry revenue over the forecast period 2020-2025.

Other additional information, such as upstream raw material and equipment development and downstream demand analysis, are discussed in detail in this report on the Stem Cell Therapy Market. This consciously designed market research protocol inspires our research experts and predictors to devote more effort to uncovering thorough information, allowing critical research colleagues and knowledge gatherers to optimally find multidimensional information for the best market forecast.

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

COVID-19 Specific Analysis

At the backdrop of sudden and lingering outbreak of COVID-19, market players drive resources towards procuring innovative means to ensure quick recovery measures.

Global Stem Cell Therapy Market Dynamics

Drivers: Prevalent across both matured economies and developing regions alike Barriers: A touchpoint featuring the core difficulties, threats and challenges experienced by market participants, also addressing threat probability Opportunities: Briefly touching on consumption and production developments, competition intensity as well as growth rate across countries and regions.

Browse full research report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

1 This high end research report representation on the Stem Cell Therapy Market is fundamentally aimed to unravel developments such as supply and demand scenario 2. The report presents a thorough investigative study of the Stem Cell Therapy Market to assist and guide profitable business discretion 3. The report follows a top down investigative approach to unravel forecast projections 4. Further, the report scouts further analysis to identify and group the eventful developments, sectioning them in fragments and categories to direct profit ventures in the Stem Cell Therapy Market, also aiding market participants business discretion.

Chapter1. Executive Summary Chapter2. Research Methodology Chapter3. Market Outlook Chapter4. Global Stem Cell Therapy Market Overview, By Type Chapter5. Global Stem Cell Therapy Market Overview, By Application Chapter6. Global Stem Cell Therapy Market Overview, By Region Chapter7. Company Profiles

Read more:
Stem Cell Therapy Market 2020 In-depth Analysis by Leading Players The Think Curiouser - The Think Curiouser

Ken Shamrock Credits Stem Cell Treatment For Being Able To Wrestle In Impact At 56 – 411mania.com

In an interview with TV Insider, Ken Shamrock spoke about how hes able to still wrestle in Impact Wrestling even at the age of 56, which he says is due to a stem cell treatment. Here are highlights:

On being in Impact Wrestling in 56: Its fun to see where I am now and look back to where I was a year or year-and-a-half ago. I basically have been out of wrestling and MMA. I took a year off. Then I had to see if I could still be in the ring. I went to Battle Championship Wrestling in Australia and did things I didnt think I could do. I did some BioXcellerator in Colombia. My body has responded well to that treatment. Being out of any competitive sport and coming back and feeling great, its almost like Ive been given the fountain of youth all over again. Ive been able to do things I actually havent done before. Now Im diving over the top rope and doing these showstoppers. To see my body respond after the layoff and the stem cell I got from BioXcelleratorit all came together, and I felt great. Thats where Im at today. People are watching me saying, How can he do that? Im fortunate the treatments have worked well for me. Im excited to be part of Impact with the Bound for Glory coming up and being inducted into the Hall of Fame. You couldnt ask for anything better.

On the Impact locker room: Since I came in, they were just starting to make those moves and bringing in different people. There were some people who had their past catch up with them. They were forced to get rid of some talent. You wonder if youre going downward because you lost some talent, but Impact to me has improved the roster by going out and finding all this talent out there to come in and fill those spots. Its exciting to see where it is right now. When I got there, its fun to watch how fast Impact was growing, how hard people are working. The dedication that is going on behind the scenes and in the ring. When youre part of a group where everyone wants to succeed, but you are not trying to step on each others toes and [instead] work together to get there, its a great environment. I was part of that at one time in WWF when they lost all this talent to WCW. They were having those wars and losing them. Then to see everyone bond together and do the job and work together with a common goal to put on the best performance There then was some big-time star power, but it took time to get there. You see guys like Bret Hart and Stone Cold Steve Austin become mega stars and The Rock and The Undertaker. There is a common goal to be successful at Impact but not try to push everybody down. Put on a great show with whoever youre working with and bring the best out of them.

On why he wanted The Rock to induct him: In life there are always people that are important pieces to your journey. They helped take you to where you needed to go and vice versa. The Rock had a career in college football with an opportunity to get to the pros from Miami. Then he chose to go into wrestling. I did my career in fighting and MMA and did well. Of course, I was going in a different direction. So I think we caught each other at a time where we were excited to find who we were and what we would become. When Vince [McMahon] put us together, it was like iron sharpening iron. I believe we really found out who we were in pro wrestling when we were able to work our programs together.

We had some great matches and were able to talk about things on the road and figure out what worked and didnt work. We were able to rise to where we are today off each other while working together. After his run, he went to the sky. I went in a different direction, but I had a similar success. Its awesome to look back on the journeys that you traveled, especially during times when you are recognized as being one of the greats and going into the Hall of Fame. You want to be able to include people who were so significant in that journey. The Rock was very significant in my journey. Thats why I reached out to him. There are several others that have also been important to the journey too. Its going to be fun to see how it all unfolds and the people involved that night. Im honored.

The rest is here:
Ken Shamrock Credits Stem Cell Treatment For Being Able To Wrestle In Impact At 56 - 411mania.com

Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 – TechnoWeekly

Prophecy Market Insights has recently published the Stem Cell Therapy informational report which evaluates market size, growth rate, profit margin, raw material availability, impact strength, competition, technology, and environmental and legal factors.

The report covers all recent trends, opportunities, drivers, and restraints of the Stem Cell Therapy market coupled with their impact on demand over the forecast period. Additionally, the report provides a comprehensive view of the market by offering exhaustive value chain analysis. It provides in-depth information about value addition at each stage of the value chain.

Comprehensive information pertaining to fire alarm systems and its properties is provided in this section. This section also highlights the inclusions and exclusions, which help readers to understand the scope of the market report.

This segment includes factors that have emerged as key successful factors and strategies adopted by key market participants.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3811

The Stem Cell Therapy market report provides a detailed analysis of market players according to its production footprint, market share, and growth rate. The report also covers SWOT analysis (strengths, weaknesses, opportunities, and threats) of the players. Besides, the Stem Cell Therapy market study depicts the recent launches, R&D projects, agreements, and business strategies of the market players including market segmentation and regional analysis of the market.

The Stem Cell Therapy market study covers both the top-down and bottom-up approaches that have been used to calculate and authenticate the market size and estimate the scenario of various sub-markets in the global market. The report estimation size of the market both in terms of volume (x units) and value (Mn/Bn USD).

Stem Cell Therapy Market by Top Manufacturers:

Scope of the Market Research Report:

The report takes into account the impact of the novel COVID-19 pandemic on the market and provides a clear assessment of the estimated market fluctuations throughout the forecast period.

Important Questions Answered in Stem Cell Therapy Market Report:

Segmentation Overview:

Global Stem Cell Therapy Market, By Treatment Type:

Global Stem Cell Therapy Market, By Cell Source:

Global Stem Cell Therapy Market, By Indication:

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3811

Reasons to purchase the XYX market:

Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Original post:
Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - TechnoWeekly

Robust Growth Of The Animal Stem Cell Therapy Market Predicted Over The Forecast Period 2017 2025 – Aerospace Journal

Animal Stem Cell Therapy Market Insights 2018, is a professional and in-depth study on the current state of the global Animal Stem Cell Therapy industry with a focus on the Global market. The report provides key statistics on the market status of the Animal Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Animal Stem Cell Therapy market covering all important parameters.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

The key points of the Animal Stem Cell Therapy Market report:

The report provides a basic overview of the Animal Stem Cell Therapy industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Animal Stem Cell Therapy industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Animal Stem Cell Therapy industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Animal Stem Cell Therapy Industry before evaluating its feasibility.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Animal Stem Cell Therapy are included:

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Reasons to Purchase this Report:

* Estimates 2018-2025 Animal Stem Cell Therapy market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Originally posted here:
Robust Growth Of The Animal Stem Cell Therapy Market Predicted Over The Forecast Period 2017 2025 - Aerospace Journal

Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS – ALS News Today

Catalent Biologics has agreed to manufactureNurOwn, the cell-based therapy by BrainStorm Cell Therapeuticsbeing evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS).

With this agreement, Catalent will produce NurOwn under current Good Manufacturing Practices standards set to ensure that batches of a medicine are produced with consistent high quality at its new 32,000-square-foot cell therapy manufacturing facility in Houston.

We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn, Chaim Lebovits, BrainStorms CEO, said in a press release.

With NurOwn, a patients mesenchymal stem cellsare collected from the bone marrow and treated in the lab to produce proteins called neurotrophic factors (NTFs), compounds that promote nervous tissue growth and survival. (Mesenchymal stem cells, orMSCs, are stem cells that can differentiate into a variety of other cell types.)

The modified cells called MSC-NTF cells are then injected into the patients spinal cord, where their NTFs are expected to promote the growth and survival of nerve cells, which are damaged over the course of ALS.

Using a patients own cells as a therapy minimizes the risk of an immune reaction, as might occur with cells from a donor.

The U.S. Food and Drug Administration has given NurOwn bothfast track and orphan drugdesignations to support and speed its development for ALS. The medicine also received orphan drug designation from the European Medicines Agency.

We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients, Lebovits added.

NurOwn showed an ability to slow progression in people with fast-progressing disease in a Phase 2 trial (NCT02017912). This led Brainstorm to open a Phase 3 trial (NCT03280056)to confirm those findings in a larger group of ALS patients.

The trial, taking place at six sites in the U.S., enrolled 200 patients and randomly assigned them to either NurOwn or a placebo, given in three intrathecal (into the spinal cord) injections at two-month intervals.

Researchers are evaluating NurOwns effectiveness using therevised amyotrophic lateral sclerosis functional rating scale(ALSFRS-R), which assesses such daily life abilities as swallowing, speaking, dressing and washing oneself, climbing stairs, and turning over in bed.

Its primary goal is to determine whether NurOwn outperforms a placebo at reducing the rate of decline in ALSFRS-R scores over six months. A change of 1.25 points or more in ALSFRS-R scores each month, compared to scores recorded prior to treatment, defines a responder.

Other trial goals include safety, the number of patients whose disease has not progressed, total ALSFRS-R decline, and overall survival. Samples of blood and cerebrospinal fluid will also be collected to evaluate biomarkers, like neurotrophic factors and immune molecules, in response to the treatment.

BrainStorm expects to deliver top-line results this year; the study is set to fully conclude in December.

Should results be positive and NurOwn be approved for clinical use, BrainStorm and Catalent will consider extending their partnership to allow for commercial manufacturing of NurOwn at the Houston facility.

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

Total Posts: 45

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Go here to see the original:
Catalent to Produce BrainStorm's NurOwn Cell Therapy for ALS - ALS News Today

Stem Cell Therapy Market Highest Growth by 2025 with Leading Players – The Think Curiouser

The global Stem Cell Therapy Market includes a thorough assessment of the industrys entire ecosystem, including regional and country-specific details of manufacturing activities, technological innovations, new investments, and milestones for market expansion. The report provides an exclusive overview of the competitive spectrum to identify major giants and ambitious players seeking to easily drive market penetration in the global Stem Cell Therapy Market ecosystem. The details of the COVID-19 impact and possible damage recovery plan have been discussed at length to guide important business decisions. The report is ready to reference documents that share important details of the market from a historical point of view, allowing readers to measure concurrent developments to make accurate growth guesses and make predictive assessments.

Download Sample PDF Brochure with Covid-19 Updates @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

In addition to adding new Stem Cell Therapy Market reports to the league, the extensively researched and prepared repository is constantly updated to ensure real-time status. Our in-house research experts continue to adhere to internationally recognized research practices to stay ahead of the competition. Our well-updated online research archives stand out across the globe and in regional areas and boast a constantly growing clientele with a dedicated presence in specific countries. As a highly preferred research and consulting service provider, we strive to address multiple industries with in-depth insights that favor error-free deductions and forward-looking insights that support future business decisions.

The main purpose of this detailed business intelligence report is to closely follow development patterns, highlight the dominant popular trends, and identify new trend analysis and new opportunities influencing value and volume-based revenue in the global Stem Cell Therapy Market. Research findings show that new and existing players across market platforms are keen to reach logical and relevant business considerations where they can leverage solid leads in addition to effectively brainstorming profitable business decisions to secure stable leads. And has been meticulously presented based on secondary research practices. Long-term revenue generation despite major dynamics changes and catastrophic changes that have a profound impact on the overall growth trajectory of the global Stem Cell Therapy Market.

Get discount on purchase at: https://www.adroitmarketresearch.com/researchreport/purchase/691?utm_source=re

Research findings show that new and existing players across market platforms are keen to reach logical and relevant business considerations where they can leverage solid leads in addition to effectively brainstorming profitable business decisions to secure stable leads. And has been meticulously presented based on secondary research practices. Long-term revenue generation despite major dynamics changes and catastrophic changes that have a profound impact on the overall growth trajectory of the global Stem Cell Therapy Market.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Primary Focus of the Stem Cell Therapy Market Report, Enlisted

1. Readers are presented with market insider report commencing with the overview section 2. Later in the report, details on manufacturer information, leading market participants as well as other key players have also been included. 3. Relevant details on market production, capacity, revenue generation in terms of value and volume based metrices have also been encapsulated in the report. 4. Above mentioned details have been systematically presented based on region as well as country-specific developments, with details about export and import activities. 5. Details pertaining to market segmentation have also been included in the Stem Cell Therapy Market report which are classified into type and application. Additional details on technological applications and milestones have also been included in the report. 6. Readers can also spot other vital details inclusive of industrial chain, downstream and upstream developments besides including details in other stakeholders such as traders, distributors as well as downstream buyers.

Browse full research report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Chapter1. Executive Summary Chapter2. Research Methodology Chapter3. Market Outlook Chapter4. Global Stem Cell Therapy Market Overview, By Type Chapter5. Global Stem Cell Therapy Market Overview, By Application Chapter6. Global Stem Cell Therapy Market Overview, By Region Chapter7. Company Profiles

View post:
Stem Cell Therapy Market Highest Growth by 2025 with Leading Players - The Think Curiouser

NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia – BioSpace

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Neximmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001. The cancer center will leverage both patient samples from the ongoing NexImmune Phase 1/2 clinical study of NEXI-001 in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic stem cell transplantation and the centers tumor repository bank of primary leukemia samples, one of the largest collections in the world, to drive the research.

NEXI-001 is a cellular product candidate that contains populations of naturally occurring CD8+ T cells directed against multiple antigen targets for AML, and it is the first clinical product generated by the Companys AIM nanoparticle technology.

NexImmune has developed a unique and versatile technology platform that lends itself very effectively to important areas of ongoing research in the field of AML, said Guido Marcucci, M.D., Chair and Professor with City of Hopes Department of Hematologic Malignancies Translational Science. Our collective goal is to translate future research findings into new, more effective T cell immunotherapies to the benefit of these very difficult to treat patients.

A key objective of the research will focus on the identification of new antigen targets that are expressed on both leukemic blasts as well as leukemic stem cells, and those which represent survival proteins to both. Once identified, these antigen targets will be loaded on NexImmune AIM-nanoparticles to expand antigen-specific CD8+ T cells, and evaluated in pre-clinical models for anti-tumor potency, tumor-specific killing, and response durability.

In addition, the research initiative will aim to further understand different mechanisms of tumor escape, such as tumor antigen and human leukocyte antigen (HLA) downregulation due to immune pressure.

Research between NexImmune and City of Hope will inform a scientific understanding of how the immune system can address certain tumor escape mechanisms to more effectively fight aggressive cancers like AML, and how this might be accomplished with NexImmunes AIM technology and T cell products, said Monzr Al Malki, M.D., Director of City of Hopes Unrelated Donor BMT Program and Haploidentical Transplant Program and an Associate Clinical Professor with Department of Hematology and Hematopoietic Cell Transplantation. Based on our current clinical experience with this technology, were excited to learn what more this research will tell us.

City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world, said Han Myint, M.D., NexImmune Chief Medical Officer. The depth of expertise that Drs. Marcucci, Al Malki and their team bring to this research initiative will help NexImmune continue to develop innovative products that can help patients with AML and other hard-to-treat cancers.

City of Hope is a leader inbone marrow transplantation. More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually. City of Hopes BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.

About NexImmune NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nanoparticles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.

NexImmunes two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Companys pipeline also has additional preclinical programs, including cell therapy and injectable product candidates, for the treatment of oncology, autoimmune disorders, and infectious diseases.

For more information, visit http://www.neximmune.com.

Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 mikebeyer@sambrown.com

Investor Contact: Chad Rubin Solebury Trout +1-646-378-2947 crubin@soleburytrout.com

Read the rest here:
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - BioSpace